1887

Abstract

Human immunodeficiency virus type 1 subtype C isolates belong to one of the most prevalent strains circulating worldwide and are responsible for the majority of new infections in the sub-Saharan region and other highly populated areas of the globe. In this work, the impact of drug-resistance mutations in the protease gene of subtype C viruses was analysed and compared with that of subtype B counterparts. A series of recombinant subtype C and B viruses was constructed carrying indinavir (IDV)-resistance mutations (M46V, I54V, V82A and L90M) and their susceptibility to six FDA-approved protease inhibitor compounds (amprenavir, indinavir, lopinavir, ritonavir, saquinavir and nelfinavir) was determined. A different impact of these mutations was found when nelfinavir and lopinavir were tested. The IDV drug-resistance mutations in the subtype C protease backbone were retained for a long period in culture without selective pressure when compared with those in subtype B counterparts in washout experiments.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81517-0
2006-05-01
2020-11-27
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/5/1303.html?itemId=/content/journal/jgv/10.1099/vir.0.81517-0&mimeType=html&fmt=ahah

References

  1. Boden D., Markowitz M. 1998; Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 42:2775–2783
    [Google Scholar]
  2. Calazans A., Brindeiro R., Brindeiro P. & 7 other authors 2005; Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 191:1961–1970 [CrossRef]
    [Google Scholar]
  3. Cane P. A., de Ruiter A., Rice P., Wiselka M., Fox R., Pillay D. 2001; Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol 39:2652–2654 [CrossRef]
    [Google Scholar]
  4. Carpenter C. C., Fischl M. A., Hammer S. M. & 11 other authors 1996; Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 276:146–154 [CrossRef]
    [Google Scholar]
  5. Carrion G., Eyzaguirre L., Montano S. M. & 18 other authors 2004; Documentation of subtype C HIV type 1 strains in Argentina, Paraguay, and Uruguay. AIDS Res Hum Retroviruses 20:1022–1025 [CrossRef]
    [Google Scholar]
  6. Condra J. H., Schleif W. A., Blahy O. M. & 12 other authors 1995; In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569–571 [CrossRef]
    [Google Scholar]
  7. Condra J. H., Holder D. J., Schleif W. A. & 20 other authors 1996; Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 70:8270–8276
    [Google Scholar]
  8. Dumans A. T., Soares M. A., Machado E. S., Hué S., Brindeiro R. M., Pillay D., Tanuri A. 2004; Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis 189:1232–1238 [CrossRef]
    [Google Scholar]
  9. García-Lerma J. G., Nidtha S., Blumoff K., Weinstock H., Heneine W. 2001; Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A 98:13907–13912 [CrossRef]
    [Google Scholar]
  10. Gonzalez L. M. F., Brindeiro R. M., Tarin M., Calazans A., Soares M. A., Cassol S., Tanuri A. 2003; In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. Antimicrob Agents Chemother 47:2817–2822 [CrossRef]
    [Google Scholar]
  11. Gonzalez L. M. F., Brindeiro R. M., Aguiar R. S., Pereira H. S., Abreu C. M., Soares M. A., Tanuri A. 2004; Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 48:3552–3555 [CrossRef]
    [Google Scholar]
  12. Goudsmit J., De Ronde A., Ho D. D., Perelson A. S. 1996; Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 70:5662–5664
    [Google Scholar]
  13. Goudsmit J., de Ronde A., de Rooij E., de Boer R. 1997; Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 71:4479–4484
    [Google Scholar]
  14. Grossman Z., Paxinos E. E., Averbuch D. & 10 other authors 2004; Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 48:2159–2165 [CrossRef]
    [Google Scholar]
  15. Gulick R. M., Mellors J. W., Havlir D. & 12 other authors 1998; Simultaneous vs sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection. JAMA 280:35–41 [CrossRef]
    [Google Scholar]
  16. Haas D. W., Zala C., Schrader S. & 6 other authors 2003; Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 17:1339–1349 [CrossRef]
    [Google Scholar]
  17. Hammer S. M., Squires K. E., Hughes M. D. & 9 other authors 1997; A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337:725–733 [CrossRef]
    [Google Scholar]
  18. Harrigan P. R., Bloor S., Larder B. A. 1998; Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 72:3773–3778
    [Google Scholar]
  19. Harrigan P. R., Montaner J. S., Wegner S. A., Verbiest W., Miller V., Wood R., Larder B. A. 2001; World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 15:1671–1677 [CrossRef]
    [Google Scholar]
  20. Hertogs K., de Béthune M.-P., Miller V. & 14 other authors 1998; A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42:269–276 [CrossRef]
    [Google Scholar]
  21. Hirsch M. S., Brun-Vézinet F., D'Aquila R. T. & 11 other authors 2000; Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society – USA panel. JAMA 283:2417–2426 [CrossRef]
    [Google Scholar]
  22. Iversen A. K. N., Shafer R. W., Wehrly K., Winters M. A., Mullins J. L., Chesebro B., Merigan T. C. 1996; Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70:1086–1090
    [Google Scholar]
  23. Jülg B., Goebel F. D. 2005; HIV genetic diversity: any implications for drug resistance?. Infection 33:299–301 [CrossRef]
    [Google Scholar]
  24. Kantor R., Katzenstein D. 2003; Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 5:25–35
    [Google Scholar]
  25. Kantor R., Machekano R., Gonzales M. J., Dupnik K., Schapiro J. M., Shafer R. W. 2001; Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 29:296–299 [CrossRef]
    [Google Scholar]
  26. Kantor R., Katzenstein D. A., Efron B. & 28 other authors 2005; Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2:e112 [CrossRef]
    [Google Scholar]
  27. Kijak G. H., Rubio A. E., Pampuro S. E., Zala C., Cahn P., Galli R., Montaner J. S., Salomón H. 2003; Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med 4:72–78 [CrossRef]
    [Google Scholar]
  28. Larder B. A., Kemp S. D., Harrigan P. R. 1995; Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696–699 [CrossRef]
    [Google Scholar]
  29. Lillehoj E. P., Salazar F. H. R., Mervis R. J., Raum M. G., Chan H. W., Ahmad N., Venkatesan S. 1988; Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus. J Virol 62:3053–3058
    [Google Scholar]
  30. Loemba H., Brenner B., Parniak M. A., Ma'ayan S., Spira B., Moisi D., Oliveira M., Detorio M., Wainberg M. A. 2002; Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 46:2087–2094 [CrossRef]
    [Google Scholar]
  31. Martinez-Picado J., Savara A. V., Sutton L., D'Aquila R. T. 1999; Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 73:3744–3752
    [Google Scholar]
  32. Maschera B., Furfine E., Blair E. D. 1995; Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 69:5431–5436
    [Google Scholar]
  33. Miller V., Sabin C., Hertogs K. & 10 other authors 2000; Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14:2857–2867 [CrossRef]
    [Google Scholar]
  34. Molla A., Korneyeva M., Gao Q. & 14 other authors 1996; Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2:760–766 [CrossRef]
    [Google Scholar]
  35. Osmanov S., Pattou C., Walker N., Schwardlander B., Esparza J. 2002; Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 29:184–190 [CrossRef]
    [Google Scholar]
  36. Patick A. K., Duran M., Cao Y. & 7 other authors 1998; Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 42:2637–2644
    [Google Scholar]
  37. Picchio G. R., Valdez H., Sabbe R., Landay A. L., Kuritzkes D. R., Lederman M. M., Mosier D. E. 2000; Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr 25:289–295 [CrossRef]
    [Google Scholar]
  38. Pieniazek D., Rayfield M., Hu D. J. & 9 other authors 2000; Protease sequences from HIV-1 group M subtypes A–H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 14:1489–1495 [CrossRef]
    [Google Scholar]
  39. Piliero P. J. 2002; Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Investig Drugs 11:1295–1301 [CrossRef]
    [Google Scholar]
  40. Puchhammer-Stöckl E., Kunz C., Faatz E., Kasper P., Heinz F. X. 1998; Introduction of HIV-1 subtypes C, E and A into Austria. Clin Diagn Virol 9:25–28 [CrossRef]
    [Google Scholar]
  41. Robertson D. L., Hahn B. H., Sharp P. M. 1995a; Recombination in AIDS viruses. J Mol Evol 40:249–259 [CrossRef]
    [Google Scholar]
  42. Robertson D. L., Sharp P. M., McCutchan F. E., Hahn B. H. 1995b; Recombination in HIV-1. Nature 374:124–126
    [Google Scholar]
  43. Ruiz L., Nijhuis M., Boucher C. & 9 other authors 1998; Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 19:19–28 [CrossRef]
    [Google Scholar]
  44. Sanne I., Piliero P., Squires K., Thiry A., Schnittman S. 2003; Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 32:18–29 [CrossRef]
    [Google Scholar]
  45. Schmidt B., Walter H., Moschik B. & 7 other authors 2000; Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS 14:1731–1738 [CrossRef]
    [Google Scholar]
  46. Schmidt B., Walter H., Zeitler N., Korn K. 2002; Genotypic drug resistance interpretation systems – the cutting edge of antiretroviral therapy. AIDS Rev 4:148–156
    [Google Scholar]
  47. Schmit J. C., Cogniaux J., Hermans P. & 8 other authors 1996; Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 174:962–968 [CrossRef]
    [Google Scholar]
  48. Shafer R. W., Hsu P., Patick A. K., Craig C., Brendel V. 1999; Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J Virol 73:6197–6202
    [Google Scholar]
  49. Sharma P. L., Crumpacker C. S. 1997; Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 71:8846–8851
    [Google Scholar]
  50. Sonnerborg A., Durdevic S., Giesecke J., Sallberg M. 1997; Dynamics of the HIV-1 subtype distribution in the Swedish HIV-1 epidemic during the period 1980 to 1993. AIDS Res Hum Retroviruses 13:343–345 [CrossRef]
    [Google Scholar]
  51. Weber J., Rangel H. R., Chakraborty B. & 12 other authors 2003; Role of baseline pol genotype in HIV-1 fitness evolution. J Acquir Immune Defic Syndr 33:448–460 [CrossRef]
    [Google Scholar]
  52. Ziermann R., Limoli K., Das K., Arnold E., Petropoulos C. J., Parkin N. T. 2000; A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol 74:4414–4419 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81517-0
Loading
/content/journal/jgv/10.1099/vir.0.81517-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error